Split History
ETFs Holding ACER »    ACER Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Acer Therapeutics is a biopharmaceutical company developing a personalized immunotherapy with the potential to treat illnesses, including multiple sclerosis as well as other autoimmune diseases such as neuromyelitis optica (NMO). Co. has been developing OPX-212 as an autologous T-cell immunotherapy for the treatment of NMO. NMO is an autoimmune disorder in which immune system cells and antibodies attack astrocytes causing to the secondary destruction of nerve cells (axons) in the optic nerves and the spinal cord. OPX-212 is specifically tailored to each patient's immune response to a protein, aquaporin-4 expressed by astrocytes, which is the targeted antigen in NMO. According to our ACER split history records, Acer Therapeutics has had 1 split.
ACER split history picture
Acer Therapeutics (ACER) has 1 split in our ACER split history database. The split for ACER took place on September 21, 2017. This was a 96 for 1000 reverse split, meaning for each 1000 shares of ACER owned pre-split, the shareholder now owned 96 shares. For example, a 1000 share position pre-split, became a 96 share position following the split.

When a company such as Acer Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share. Looking at the ACER split history from start to finish, an original position size of 1000 shares would have turned into 96 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Acer Therapeutics shares, starting with a $10,000 purchase of ACER, presented on a split-history-adjusted basis factoring in the complete ACER split history. ACER split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 05/27/2008
End date: 05/23/2018
Start price/share: $9.27
End price/share: $18.80
Dividends collected/share: $0.00
Total return: 102.80%
Average Annual Total Return: 7.33%
Starting investment: $10,000.00
Ending investment: $20,278.83
Years: 9.99
Date Ratio
09/21/201796 for 1000
ACER is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

ACET Split History
ACHC Split History
ACHV Split History
ACST Split History
ACUR Split History
ADK Split History
ADMP Split History
ADMS Split History
ADPT Split History
ADXS Split History

PREMIER FINANCIAL BANCORP, INC. (PFBI)
Horizon Bancorp, Inc. (HBNC)
Exponent, Inc. (EXPO)
BIOLASE, Inc. (BIOL)
Jewett-Cameron Trading Company Ltd. (JCTCF)
ProShares UltraShort Basic Materials (SMN)
ProShares Short Financials (SEF)
ProShares UltraPro Short Nasdaq Biotechnology (ZBIO)
ProShares UltraShort Semiconductors (SSG)
ProShares UltraShort FTSE China 50 (FXP)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

ACER Insider Buying

ACER Split History | www.SplitHistory.com | Copyright © 2013 - 2018, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.